Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated February 26, 2025, reports a significant corporate action regarding major shareholdings. The filing serves as a notification of the conversion of American Depositary Shares (ADS) into ordinary shares by a major shareholder.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure regarding equity ownership structure.
Material Changes
- Share Conversion: Pfizer Inc. converted its holding of American Depositary Shares into Haleon ordinary shares.
- Ownership Structure: Pfizer holds its Haleon ordinary shares through State Street Nominees Limited, which holds legal title on Pfizer's behalf.
- Voting Rights: As of February 24, 2025, Pfizer's total voting rights remained at 7.31% (661,709,764 voting rights). There was no change in the percentage of voting rights held, only a change in the instrument type (from ADS to ordinary shares).
- Share Capital Basis: Calculations are based on Haleon's issued voting share capital of 9,054,145,714 ordinary shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a standard notification form (TR-1) required for major holdings.
Investor Verification Checklist
- Verify the total issued voting share capital of Haleon Plc (stated as 9,054,145,714 shares).
- Confirm Pfizer Inc.'s continued ownership percentage of 7.31% following the ADS conversion.
- Review the announcement dated February 3, 2025, regarding total voting rights and capital to validate the share count basis.
- Check for any subsequent filings regarding further changes in Pfizer's stake or other major shareholder movements.